Fused Or Hybrid Cell, Per Se Patents (Class 435/346)
-
Patent number: 8119774Abstract: The present invention provides a cell marker that is characterized by binding to a GCTM-5 antibody of active fragment. The cell marker identifies a unique sub-population of stem cells that show characteristics of hepatic or pancreatic stem cells or hepatic or pancreatic progenitor cells. More specifically the marker is an early liver marker, which could prove a useful tool for the isolation and identification of liver and pancreatic progenitors for both diseased adult liver and differentiating human embryonic stem cells.Type: GrantFiled: October 8, 2004Date of Patent: February 21, 2012Inventors: Martin Pera, Susan Hawes, Lincon Stamp, Heather Crosby, Alastair Strain
-
Patent number: 8119120Abstract: Methods disclosed include methods of treating T1DM, said method comprising delivering a therapeutic amount of ?-MSC to a subject in need thereof. Further disclosed are fusion cells comprising and MSC and a second cell wherein the nuclei of the MSC and the second cell are not fused in the fusion cell.Type: GrantFiled: September 19, 2007Date of Patent: February 21, 2012Assignee: Insugen, LLCInventor: Christof Westenfelder
-
Patent number: 8114666Abstract: The present invention relates to the field of animal health and in particular to Lawsonia intracellularis. In particular, the invention relates to a method of diagnosing Lawsonia intracellularis infection and a diagnostic test kit using Lawsonia intracellularis-specific antibodies. The invention also relates to the use of the method or test kit for diagnosing Lawsonia intracellularis infections.Type: GrantFiled: July 19, 2011Date of Patent: February 14, 2012Assignee: Boehringer Ingelheim Vetmedica GmbHInventor: Malik Merza
-
Patent number: 8114667Abstract: The present invention relates to the field of animal health and in particular to Lawsonia intracellularis. In particular, the invention relates to a method of diagnosing Lawsonia intracellularis infection and a diagnostic test kit using Lawsonia intracellularis-specific antibodies. The invention also relates to the use of the method or test kit for diagnosing Lawsonia intracellularis infections.Type: GrantFiled: July 19, 2011Date of Patent: February 14, 2012Assignee: Boehringer Ingelheim Vetmedica GmbHInventor: Malik Merza
-
Publication number: 20120020972Abstract: The present disclosure relates to antibodies and immunoassay methods for use in the diagnosis, treatment and prevention of hepatocellular carcinoma (HCC), liver cancer and related conditions.Type: ApplicationFiled: July 26, 2010Publication date: January 26, 2012Applicant: ABBOTT LABORATORIESInventors: Toru Yoshimura, Barry Lee Dowell, Gangamani S. Beligere, Eisaku Yoshida
-
Publication number: 20110318355Abstract: The present application concerns mutant proteins of the fusion protein (F protein) of the parainfluenza virus (PIV) which are currently indexed as type 5 PIV (PIV-5 or PIV5) and type 2 PIV (PIV-2 or PIV2). The present application concerns products deriving therefrom, such as: nucleic acids, vectors, cells, fusion inhibitors of the antibody, aptamer, interfering RNA type; myelomas, hybridomas; stem and progenitor cells. The present application also concerns mutant proteins and products derived therefrom for use in medical and biotechnological applications.Type: ApplicationFiled: November 17, 2009Publication date: December 29, 2011Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, LES HOSPICES CIVILS DE LYON, UNIVERSITE CLAUDE BERNARD DE LYON 1Inventors: Manuel Melchior Jean-Pierre Rosa Calatrava, Olivier Terrier, Francois Edouard Julien Durupt
-
Publication number: 20110318312Abstract: Certain embodiments disclosed herein include, but are not limited to, at least one of compositions, methods, devices, systems, kits, or products regarding rejuvenation or preservation of germ cells or gametes. Certain embodiments disclosed herein include, but are not limited to, methods of modifying germ cells or gametes, or methods of administering modified germ cells or gametes to at least one biological tissue.Type: ApplicationFiled: June 24, 2010Publication date: December 29, 2011Inventors: Roderick A. Hyde, Edward K.Y. Jung, Lowell L. Wood, JR.
-
Publication number: 20110311498Abstract: Disclosure of a mammalian cytoplasmic donor cell line. Disclosure of a patient specific cell line. Disclosure of a method to obtain a mammalian cytoplasmic donor cell line by fusing a differentiated mammalian cell and a functionally enucleated mammalian embryonic cell line. Disclosure of a method to obtain a patient specific cell line of a cell type similar to a mammalian cytoplasmic donor cell line by functionally enucleating the mammalian cytoplasmic donor cell line and fusing the functionally enucleated mammalian cytoplasmic donor cell line with a differentiated cell obtained from the patient. A method of treatment administering the patient-specific cell line to the patient.Type: ApplicationFiled: October 26, 2009Publication date: December 22, 2011Inventor: Thiru V. Gopal
-
Publication number: 20110311541Abstract: The present application concerns mutant proteins of the fusion protein (F protein) of the parainfluenza virus (PIV) which are currently indexed as type 5 PIV (PIV-5 or PIV5) and type 2 PIV (PIV-2 or PIV2). The present application concerns products deriving therefrom, such as: nucleic acids, vectors, cells, fusion inhibitors of the antibody, aptamer, interfering RNA type; myelomas, hybridomas; stem and progenitor cells. The present application also concerns mutant proteins and products derived therefrom for use in medical and biotechnological applications.Type: ApplicationFiled: November 17, 2009Publication date: December 22, 2011Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, LES HOSPICES CIVILS DE LYON, UNIVERSITE CLAUDE BERNARD DE LYON 1Inventors: Manuel Melchior Jean-Pierre Rosa Calatrava, Olivier Terrier, Francois Edouard Julien Durupt
-
Publication number: 20110300128Abstract: The present invention is directed to a method for detecting abnormal lymphocytes said method comprising detecting an amount or expression of the FOXP2 gene in lymphocytes in a sample, wherein an increased amount or expression of the FOXP2 gene in said lymphocytes indicates the presence of abnormal lymphocytes. Additionally, the invention concerns a method for detecting or assessing a condition associated with the presence of abnormal lymphocytes. The methods of the invention may also be useful for diagnosing myeloma or MGUS or for determining the prognosis for patients with lymphoma, myeloma or MGUS. The severity of bone disease or bone colonisation of tumours may also be able to be predicted. Further, treatment of conditions associated with the presence of abnormal lymphocytes using an agent which inhibits FOXP2 expression and/or FOXP2 activity is provided. An antibody which binds to the N-terminus of FOXP2 has also been developed.Type: ApplicationFiled: December 16, 2009Publication date: December 8, 2011Applicant: ISIS INNOVATION LIMITEDInventors: Alison Banham, Andrew Campbell, Duncan Gascoyne, Linden Lyne
-
Patent number: 8071371Abstract: A method for producing a clone of an immortalized human B memory lymphocyte, comprising the step of transforming human B memory lymphocytes using Epstein Barr Virus (EBV) in the presence of a polyclonal B cell activator. The method is particularly useful in a method for producing a clone of an immortalized human B memory lymphocyte capable of producing a human monoclonal antibody with a desired antigen specificity, comprising the steps of: (i) selecting and isolating a human memory B lymphocyte subpopulation; (ii) transforming the subpopulation with Epstein Barr Virus (EBV) in the presence of a polyclonal B cell activator; (iii) screening the culture supernatant for antigen specificity; and (iv) isolating an immortalized human B memory lymphocyte clone capable of producing a human monoclonal antibody having the desired antigen specificity.Type: GrantFiled: February 26, 2004Date of Patent: December 6, 2011Assignee: Humabs LLCInventor: Antonio Lanzavecchia
-
Publication number: 20110294678Abstract: Provided are a method and means permitting the simultaneous measurement of the reactive properties of more than 10,000 of antigen-stimulated lymphocytes being held on a chip and the separate determination of the states of individual cells. A microwell array comprises multiple wells and a coating layer on one of the principal surfaces of a base member, the wells being of a size permitting the entry of only a single cell into each well. A coating layer of a substance capable of binding to a substance produced by the cells contained in the wells is present on the principal surface around the wells.Type: ApplicationFiled: August 1, 2008Publication date: December 1, 2011Applicants: SC World Inc., Toyama PrefectureInventors: Aishun Jin, Hiroyuki Kishi, Atsushi Muraguchi, Tsutomu Obata
-
Publication number: 20110294208Abstract: An apparatus for collecting or culturing cells or cell colonies has a common substrate and a plurality of cell carriers releasably connected to the common substrate. The carriers are arranged in the form of an array. The invention employs microcups as the cell carriers. The substrate is preferably free of barriers between the microcups, and in some embodiments the microcups have porous walls. Methods of using the apparatus are also described.Type: ApplicationFiled: February 11, 2010Publication date: December 1, 2011Inventors: Nancy Allbritton, Christopher Sims, Wei Xu
-
Publication number: 20110293580Abstract: Methods for obtaining pluripotent (embryonic stem) cells from parthenogenetic embryos, especially primates, are provided. These cells are useful for producing differentiated cells, tissues and organs, especially human and non-human primate cells, tissues and organs.Type: ApplicationFiled: May 27, 2011Publication date: December 1, 2011Applicant: Advanced Cell Technology, Inc.Inventors: James M. ROBL, Jose Cibelli, Amy Burnside
-
Patent number: 8067564Abstract: Specific binding members directed to eotaxin-1, in particular human antibodies and antibody fragments against human eotaxin-1 and especially those which neutralize eotaxin-1 activity. The antibodies VH and/or VL domain of the scFv fragment herein termed CAT-212 and of the IgG4 antibody herein termed CAT 213. One or more complementary determining regions (CDRs) of the CAT-212/-213 VH and/or VL domains, especially VH CRD3 in other antibody framework regions. Compositions containing specific binding members, and their use in methods of inhibiting or neutralizing eotaxin, including methods of treatment of the human or animal body by therapy.Type: GrantFiled: December 17, 2007Date of Patent: November 29, 2011Assignee: MedImmune LimitedInventors: Tristan John Vaughan, Alison Jane Wilton, Stephen Smith, Sarah Helen Main
-
Patent number: 8058062Abstract: The present invention relates to the field of animal health and in particular to Lawsonia intracellularis. In particular, the invention relates to a method of diagnosing Lawsonia intracellularis infection and a diagnostic test kit using Lawsonia intracellularis-specific antibodies. The invention also relates to the use of the method or test kit for diagnosing Lawsonia intracellularis infections.Type: GrantFiled: July 19, 2011Date of Patent: November 15, 2011Assignee: Boehringer Ingelheim Vetmedica GmbHInventor: Malik Merza
-
Publication number: 20110275149Abstract: The present invention relates to the field of animal health and in particular to Lawsonia intracellularis. In particular, the invention relates to a method of diagnosing Lawsonia intracellularis infection and a diagnostic test kit using Lawsonia intracellularis-specific antibodies. The invention also relates to the use of the method or test kit for diagnosing Lawsonia intracellularis infections.Type: ApplicationFiled: July 19, 2011Publication date: November 10, 2011Applicant: BOEHRINGER INGELHEIM VETMEDICA GMBHInventor: Malik MERZA
-
Publication number: 20110275121Abstract: The method of the invention provides for producing a heterologous protein in mammalian host cells having nucleic acid encoding Hepatitis B X protein and the heterologous protein, by growing mammalian host cells selected from the group consisting of HKB11, CHO, BHK21, C2C12, and HEK293 cells, by growing mammalian host cells in non-adherent suspension culture, or by growing mammalian host cells which contain nucleic acid providing exogenous X-box Binding Protein, XBP1s. The conditions should be such that HBx, exogenous XBP1s if present, and the heterologous protein are expressed by the mammalian cells. The invention includes compositions for carrying out the method.Type: ApplicationFiled: May 27, 2009Publication date: November 10, 2011Applicant: BAYER HEALTHCARE LLCInventors: Fang Jin, Richard N. Harkins, Maxine Bauzon, Terry Hermiston
-
Patent number: 8044180Abstract: The present invention relates to antibodies or fragments thereof that specifically bind Fc?RIIB, particularly human Fc?RIIB, with greater affinity than said antibodies or fragments thereof bind Fc?RIIA, particularly human Fc?RIIA. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention.Type: GrantFiled: July 3, 2008Date of Patent: October 25, 2011Assignee: MacroGenics, Inc.Inventors: Scott Koenig, Maria Concetta Veri
-
Publication number: 20110243895Abstract: Disclosure of a mammalian cytoplasmic donor cell line. Disclosure of a patient specific cell line. Methods to obtain a mammalian cytoplasmic donor cell line by fusing a differentiated mammalian cell and a functionally enucleated mammalian embryonic cell line. Methods to obtain a mammalian cytoplasmic donor cell line by fusing a differentiated mammalian cell and a functionally enucleated human cancer cell. Methods to obtain a patient specific cell line of a cell type similar to a mammalian cytoplasmic donor cell line by functionally enucleating the mammalian cytoplasmic donor cell line and fusing the functionally enucleated mammalian cytoplasmic donor cell line with a differentiated cell obtained from the patient. A method of treatment of a human patient by administering the patient-specific cell line to the patient.Type: ApplicationFiled: April 14, 2011Publication date: October 6, 2011Inventor: Thiru V. Gopal
-
Publication number: 20110236455Abstract: The present invention relates to the identification of novel regulators of the innate immune system, in particular the complement system. More particularly, the present invention relates to specific C5 convertase inhibitors. These novel inhibitors are particularly useful for treating inflammatory diseases involving the complement system. In a first aspect, the present invention focuses on the use of CFHR proteins and functional fragments or functional derivatives thereof for preventing inflammatory reactions. In a further aspect, the present invention focuses on the use of said CFHR proteins for inactivating complement activation during transplantation and dialysis and for coating devices which come into contact with blood or body fluids, in particular implants. The invention furthermore provides a pharmaceutical composition comprising functional CFHR protein in combination with functional factor H.Type: ApplicationFiled: September 28, 2009Publication date: September 29, 2011Inventors: Peter Zipfel, Christina Skerka, Reinhard Wallich
-
Patent number: 8025881Abstract: When an anti-human BMP antibody was added to cells of an immortalized human mesangial cell line cultured in the presence of human BMP, the anti-human BMP antibody significantly suppressed the production of type IV collagen in mesangial cells. A number of signaling pathways are involved in abnormal proliferation of type IV collagen. It was therefore completely unpredictable whether merely blocking the BMP signal would indeed suppress the abnormal proliferation of type IV collagen. However, for the first time, the present inventors demonstrated that anti-BMP antibodies are very effective in suppressing the abnormal proliferation of type IV collagen. Thus, anti-BMP antibodies can be used as novel therapeutic agents for kidney diseases associated with abnormal proliferation of the mesangial matrix.Type: GrantFiled: July 19, 2007Date of Patent: September 27, 2011Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Toshio Doi, Hideharu Abe, Naoshi Fukushima, Hitoshi Tai, Takakazu Mizuno, Masahiko Kinosaki
-
Publication number: 20110223160Abstract: The present disclosure provides compositions and methods relating to antigen binding proteins, in particular, antibodies which specifically bind to the human glucagon receptor. The disclosure provides nucleic acids encoding such antigen binding proteins and antibodies and methods of making and using such antibodies including methods of treating and preventing type 2 diabetes and related disorders by administering such antibodies to a subject in need of such treatment.Type: ApplicationFiled: May 23, 2011Publication date: September 15, 2011Applicant: Amgen Inc.Inventors: Hai Yan, Shaw-Fen Sylvia Hu, Thomas C. Boone, Richard A. Lindberg
-
Publication number: 20110212109Abstract: The subject invention relates to monoclonal antibodies that may be used in the treatment and diagnosis of Alzheimer's Disease. In particular, the present invention relates to monoclonal antibodies referred to as 10F4 and 3C5 and to other monoclonal antibodies (e.g., murine, human or humanized) having similar properties thereto.Type: ApplicationFiled: May 6, 2011Publication date: September 1, 2011Inventors: Stefan Barghorn, Heinz Hillen, Andreas R. Striebinger, Boris Labkovsky, Ulrich Ebert, Patrick Keller
-
Publication number: 20110206663Abstract: The present invention relates generally to the generation and characterization of neutralizing anti-IFN-? monoclonal antibodies with broad reactivity against various IFN-? subtypes. The invention further relates to the use of such anti-IFN-? antibodies in the diagnosis and treatment of disorders associated with increased expression of IFN-?, in particular, autoimmune disorders such as insulin-dependent diabetes mellitus (IDDM) and systemic lupus erythematosus (SLE).Type: ApplicationFiled: February 24, 2011Publication date: August 25, 2011Applicant: Genentech, Inc.Inventors: Anan Chuntharapai, Jin K. Kim, Leonard G. Presta, Timothy Stewart
-
Publication number: 20110189696Abstract: The present invention relates to a monoclonal antibody designated STRO-4 which specifically binds human and ovine HSP-90beta and its use for enriching multipotential cells such a mesenchymal precursor cells (MPCs).Type: ApplicationFiled: August 18, 2009Publication date: August 4, 2011Inventors: Stan Gronthos, Andrew Christopher Williem Zannellino
-
Publication number: 20110177599Abstract: The present invention provides for methods and compositions for introducing integral membrane proteins into cell membranes and, optionally, delivery of nucleic acids across membranes via the integral membrane proteins.Type: ApplicationFiled: July 20, 2010Publication date: July 21, 2011Applicant: Bio-Rad Laboratories, Inc.Inventor: Camille Diges
-
Publication number: 20110177087Abstract: The invention described herein provides for human antibodies produced in non-human animals that specifically bind to lipopolysaccharide (LPS) from strains Fisher Devlin (International Serogroups) It-2 (011), It-3 (02), It-4 (01), It-5 (010), It-6 (07), PA01 (05), 170003 (02), IATS016 (02/05), and 170006 (02). The invention further provides methods for making the antibodies in a non-human animal, expression of the antibodies in cell lines including hybridomas and recombinant host cell systems. Also provided are kits and pharmaceutical compositions comprising the antibodies and methods of treating or preventing pseudomonas infection by administering to a patient the pharmaceutical compositions described herein.Type: ApplicationFiled: July 13, 2010Publication date: July 21, 2011Inventor: John R. Schreiber
-
Publication number: 20110162093Abstract: [Problems to be Solved] The present invention provides methods for producing antibodies and antibody-producing cells. [Means for Solving the Problems] The present invention provides methods for producing antibodies or antibody-producing cells, such methods including the steps of inoculating non-human animals with minus-strand RNA viral vectors carrying nucleic acids which encode foreign polypeptides to be used as antigens, nucleic acids producing the viral vectors, cells into which the vectors or the nucleic acids producing the vectors have been introduced, or lysates of the cells; and collecting the antibodies or antibody-producing cells from the animals. The antibody production can be induced efficiently by the immune activating effect of the minus-strand RNA viral vectors and a high expression of the antigen polypeptides. The antibodies produced by the methods of the present invention can be used in research and development and in the clinical field.Type: ApplicationFiled: June 13, 2006Publication date: June 30, 2011Inventors: Yasuji Ueda, Hiroto Hara, Tsugumine Shu, Mamoru Hasegawa
-
Publication number: 20110150887Abstract: The invention relates to methods and compositions for regulation of GSK3? activity. The invention provides phosphorylated GSK3? polypeptides and antibodies that recognize such polypeptides. The invention further includes methods for treating disorders that are associated with elevated or reduced GSK3? activity.Type: ApplicationFiled: April 29, 2009Publication date: June 23, 2011Applicant: University of Vermont and State Agricultural CollegeInventors: Mercedes Rincon, Tina M. Thornton
-
Publication number: 20110129481Abstract: Antibodies specifically binding to c-Met protein, hybridoma cell lines, and compositions comprising the antibodies are disclosed herein. Methods of making and using the antibodies and compositions are also disclosed.Type: ApplicationFiled: August 30, 2010Publication date: June 2, 2011Applicant: SAMSUNG ELECTRONICS CO., LTD.Inventors: Kwang Ho Cheong, Sung-young Jeong, Sang-hyun Paek
-
Publication number: 20110123557Abstract: This invention concerns a panel of monoclonal antibodies against the High Mobility Group A 1 protein (HMGA1) and a process for preparing them, as well as the use of said antibodies for the quantitative determination of HMGA1 in biological fluids or in protein Iy sates deriving from lymphocyte cells. This invention also concerns a diagnostic kit for assessing risk factors related to the expression of the HMGA1 proteins.Type: ApplicationFiled: April 29, 2009Publication date: May 26, 2011Inventors: Alfredo Fusco, Antonio Orlandi, Maria Luisa Nolli
-
Publication number: 20110104176Abstract: Antibodies specifically binding to c-Met protein, hybridoma cell lines, and compositions comprising the antibodies are disclosed herein. Methods of making and using the antibodies and compositions are also disclosed.Type: ApplicationFiled: October 19, 2010Publication date: May 5, 2011Applicant: SAMSUNG ELECTRONICS CO., LTD.Inventors: Kwang Ho CHEONG, Sang-hyun PAEK
-
Publication number: 20110086029Abstract: The present invention provides antibodies that target the first-third domains of N-cadherein and the fourth domain of N-cadherin, for diagnosis and therapy of cancers related to N-cadherein. Methods of diagnosis and treatment utilizing these antibodies are also described.Type: ApplicationFiled: September 30, 2010Publication date: April 14, 2011Applicant: The Regents of the University of CaliforniaInventors: Robert E. Reiter, Zev Wainberg
-
Patent number: 7919314Abstract: Provided is a use of a recombinant chimaeric protein as an immunogen in a process for producing a monoclonal antibody, wherein the recombinant chimaeric protein is assembled into a virus-like particles, and includes a foreign protein or peptide or a fragment thereof.Type: GrantFiled: October 12, 2007Date of Patent: April 5, 2011Assignee: Biotechnologijos InstitutasInventors: Aurelija Zvirbliene, Alma Gedvilaite, Rainer Ulrich, Kestutis Sasnauskas
-
Publication number: 20110076700Abstract: It is intended to provide means capable of specifically recognizing CRP in a test sample and assaying it with high sensitivity. The present invention provides an anti-CRP antibody which reacts with a C-reactive protein (hereinafter referred to as CRP) and recognizes an epitope located at residues 147 to 172 in a CRP amino acid sequence represented by SEQ ID NO: 1.Type: ApplicationFiled: August 29, 2008Publication date: March 31, 2011Applicant: Nihon UniversityInventors: Hideki Kohno, Maho Kikuchi, Tomoe Komoriya
-
Publication number: 20110065184Abstract: The present invention relates to a human host cell generated from fusion of a human embryonic kidney-derived cell and a human B-cell-derived cell, by using genetic engineering techniques. The human host cell with stable characteristics well preserved may be efficiently used to produce heterologous desired recombinant protein-based pharmaceuticals.Type: ApplicationFiled: April 10, 2009Publication date: March 17, 2011Applicant: CELLTRION, INC.Inventors: HyunJoo Lee, JongMook Kim, MinSeok Chang
-
Publication number: 20110052608Abstract: The present invention relates to a novel antibody which selectively binds to the disease associated form of prion protein (PrPSc) under native conditions and the use thereof in methods of prion disease detection, therapy and disease research in general.Type: ApplicationFiled: June 13, 2007Publication date: March 3, 2011Applicant: UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGHInventors: Mark William Head, Michael Jones
-
Patent number: 7897733Abstract: Provided are rapamycin conjugates which are useful as immunogenic molecules for the generation of antibodies specific for rapamycin, for measuring levels of rapamycin or derivatives thereof; for isolating rapamycin binding proteins; and detecting antibodies specific for rapamycin or derivatives thereof. This invention also provides a rapamycin specific monoclonal antibody.Type: GrantFiled: November 14, 2005Date of Patent: March 1, 2011Assignee: Pfizer, Inc.Inventors: Katherine L. Molnar-Kimber, Craig E. Caufield, Timothy D. Ocain
-
Publication number: 20110044984Abstract: The present inventors have succeeded in producing anti-AXL antibodies with specific functions. The present inventors also discovered that the antibodies have an angiogenesis-suppressive effect and an antitumor effect, and thereby completed the present invention. The anti-AXL antibodies of the present invention are useful as angiogenesis inhibitors and agents for inducing or inhibiting phosphorylation activity.Type: ApplicationFiled: November 14, 2008Publication date: February 24, 2011Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Takehisa Kitazawa, Tsukasa Suzuki, Shigehisa Nagahashi, Hajime Miyamoto
-
Publication number: 20110045519Abstract: The invention relates to cell lines from differentiated cells with hepatocytic phenotypes capable of producing albumin and blood coagulation factors, said cells being derived from a human leukaemia cell line, preferably the human THP1 cell line, and preserving the characteristics of immortality. Among the cell lines of the invention, the cell lines known as PSC-THP1-EP, PSC-THP1-EP-FAST, PSC-THP1-HEP and PSC-THP1-EPEP are preferred. The invention also relates to methods for obtaining the cell lines of the invention and the uses of said cell lines, particularly for the production of albumin and/or blood coagulation factors.Type: ApplicationFiled: December 21, 2007Publication date: February 24, 2011Inventors: Luisa Gennero, Antonio Ponzetto, Giampiero Pescarmona, Andrea Savarino, Gianfranco Merizzi
-
Publication number: 20110039330Abstract: The present invention provides serum-free cell culture media formulations which are capable of supporting the in vitro cultivation of animal cells. The media comprise at least one nutrient of non-animal derivation, such as at least one plant peptide and/or at least one non-animal or plant lipid and/or fatty acid. The media may further optionally comprise an enzymatic digest or extract of yeast cells. The present invention also provides methods of cultivating animal cells in vitro using these cell culture media formulations. In addition, the media of the present invention can be used for growth of animal cells for virus production.Type: ApplicationFiled: April 14, 2010Publication date: February 17, 2011Applicant: LIFE TECHNOLOGIES CORPORATIONInventors: Paul PRICE, Steve Gorfien, Douglas Danner, Mark Plavsic
-
Publication number: 20110039331Abstract: The present invention provides a tag peptide comprising an amino acid sequence represented by the following formula (I): X1-Tyr-X2-Gly-Gln-X3??(I) (wherein X1, X2 and X3 are the same or different and each represent any amino acid residue) and an antibody against the tag peptide. By combined use of the tag peptide and antibody of the present invention, a system that enables proteins expressed from cloned genes to be highly purified in an inexpensive and easy manner can be established.Type: ApplicationFiled: December 18, 2008Publication date: February 17, 2011Inventor: Junichi Takagi
-
Publication number: 20110033870Abstract: The present invention relates to the field of animal health and in particular to Lawsonia intracellularis. In particular, the invention relates to a method of diagnosing Lawsonia intracellularis infection and a diagnostic test kit using Lawsonia intracellularis-specific antibodies. The invention also relates to the use of the method or test kit for diagnosing Lawsonia intracellularis infections.Type: ApplicationFiled: August 11, 2010Publication date: February 10, 2011Applicant: BOEHRINGER INGELHEIM VETMEDICA GMBHInventor: Malik MERZA
-
Publication number: 20110020928Abstract: A method of transferring a biologically active principle of interest into a cell by coupling an antibody or a fragment of an antibody, which recognizes an epitope contained in a nucleic acid, with the biologically active principle, to form a coupled biologically active principle; and incubating the coupled biologically active principle, which is transferred through the cell membrane and into the cell, with the cell.Type: ApplicationFiled: October 6, 2010Publication date: January 27, 2011Applicants: INSTITUT PASTEUR, Universite Pierre et Marie CurieInventors: Stratis AVRAMEAS, Gerard Buttin, Therese Ternynck, Faridabano Nato, Alexandre Avrameas
-
Publication number: 20110014117Abstract: The present invention relates in part to anti-IGF1R antibodies and antigen-binding compositions thereof along with methods of use thereof. For example, methods of treating medical disorders such as cancer are covered.Type: ApplicationFiled: June 25, 2008Publication date: January 20, 2011Inventors: Yan Wang, Jonathan A. Pachter, Judith Anne Hailey, Peter Brams, Denise Williams, Mohan Srinivasan, Mary Diane Feingersh
-
Publication number: 20110014200Abstract: This invention describes monoclonal antibodies that suppress thyrotropin receptor constitutive activity and methods of using the antibodies to treat thyroid related diseases; particularly hyperthyroidism and thyroid cancerType: ApplicationFiled: January 24, 2008Publication date: January 20, 2011Applicant: CEDARS-SINAI MEDICAL CENTERInventors: Basil Rapoport, Sandra McLachlan, Chun-Rong Chen
-
Publication number: 20110008354Abstract: Novel polypeptides, designated Apo-2, which are capable of modulating apoptosis are provided. Compositions including Apo-2 chimeras, nucleic acid encoding Apo-2, and antibodies to Apo-2 are also provided.Type: ApplicationFiled: August 19, 2010Publication date: January 13, 2011Applicant: GENENTECH, INC.Inventors: CAMELLIA W. ADAMS, AVI J. ASHKENAZI, ANAN CHUNTHARAPAI, KYUNG JIN KIM
-
Publication number: 20110008344Abstract: This invention relates to a novel fusion partner cell line that ectopically expresses IL-6 and TERT termed B5-6T, and to methods for making the B5-6T fusion partner cell line. The B5-6T fusion partner cell line can be fused with B-lymphocytes to generate hybridomas that secrete human monoclonal antibodies.Type: ApplicationFiled: January 28, 2009Publication date: January 13, 2011Applicant: THOMAS JEFFERSON UNIVERSITYInventors: Scott K. Dessain, Sharad P. Adekar
-
Publication number: 20110008323Abstract: The present invention relates to Cadherin-11 antagonists and compositions comprising Cadherin-11 antagonists. The invention also relates to methods for treating inflammatory joint disorders, such as rheumaotid arthritis, in a mammalian subject by administering a therapeutically effective amount of a Cadherin-11 antagonist.Type: ApplicationFiled: January 9, 2009Publication date: January 13, 2011Applicant: SYNOVEX CORPORATIONInventor: James G. McArthur